BGMS - Cyclacel Pharmaceuticals, Inc.
0.95
-0.010 -1.063%
Share volume: 18,854
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$0.96
-0.01
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-14-2024 | 11-12-2024 | 05-14-2025 | 08-14-2025 | 11-13-2025 | |
| Total revenue | 58.000 K | 20.000 K | 0.000 | 0.000 | 81.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 64.000 K | |
| Gross profit | 58.000 K | 20.000 K | 0.000 | 0.000 | 17.000 K | |
| -65.52% | -100.00% | nan% | inf% | |||
| Operating expenses | 4.384 M | 2.187 M | 5.036 M | 1.317 M | 1.009 M | |
| Selling general and admin | 1.582 M | 1.237 M | 4.214 M | 1.249 M | 1.004 M | |
| Research and development | 2.802 M | 950.000 K | 822.000 K | 68.000 K | 5.000 K | |
| Total expenses | 4.384 M | 2.187 M | 5.036 M | 1.317 M | 1.009 M | |
| -50.11% | 130.27% | -73.85% | -23.39% | |||
| Operating income | -4.355 M | -2.177 M | -5.036 M | -1.317 M | -992.000 K | |
| Ebit | -4.302 M | -2.175 M | -5.034 M | -1.318 M | -997.000 K | |
| Pretax income | -4.300 M | -2.167 M | -81.000 K | -1.316 M | -988.000 K | |
| -49.60% | -96.26% | 1,524.69% | -24.92% | |||
| Income tax | -1.354 M | -210.000 K | 0.000 | 2.000 K | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -2.946 M | -1.957 M | -81.000 K | -1.318 M | -988.000 K | |
| 33.57% | 95.86% | -1,527.16% | 25.04% |